Partnerships, Licensing, Investments and M&A Deals and Trends for October 2015 in Pharmaceuticals

Home/Partnerships, Licensing, Investments and M&A Deals and Trends for October 2015 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2015 in Pharmaceuticals

Research & Development (Pharma & Healthcare), Regulation & Policy (Pharma & Healthcare), Finance & Investment (Pharma & Healthcare), Deals & Alliances (Pharma & Healthcare), Pharma & Healthcare

Publication ID:

GDA1215032

Publication Date:

December 01, 2015

Pages:

100

Publisher:

GlobalData

Region:

Global

$1,000.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2015 in Pharmaceuticals

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for October 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in October 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, October 2015 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, October 2015 14
2.2.1 Teva Pharma to Acquire Rimsa for USD2.3 Billion 14
2.2.2 Bristol-Myers Squibb Enters into Licensing Agreement with Five Prime Therapeutics 14
2.2.3 CITIC Private Equity Funds Management to Acquire Biosensors International 17
2.2.4 Charterhouse Capital Partners to Acquire Cooper for USD799 Million from Caravelle 17
2.2.5 Concordia Healthcare Raises USD790 Million in Private Placement of 9.5% Notes Due 2022 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, October 2015 18
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, October 2015 19
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
3.1 Pharmaceuticals & Healthcare, Global, M&A, October 2015 20
3.1.1 Top M&A Deals in October 2015 21
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, May 2015 - October 2015 22
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, October 2015 24
3.2.1 Top Equity Offering Deals in October 2015 25
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, May 2015 - October 2015 26
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, October 2015 27
3.3.1 Top PE/VC Deals in October 2015 28
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, October 2015 29
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, October 2015 30
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, May 2015-October 2015 32
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2015-October 2015 33
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2015 34
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2015 34
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, May 2015 - October 2015 36
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), October 2015 37
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, October 2015 38
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2015 - October 2015 39
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, May 2015 - October 2015 41
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), May 2015 - October 2015 42
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2015 - October 2015 44
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2015 46
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2015 46
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 48
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), May 2015 - October 2015 50
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2015 - October 2015 52
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2015 - October 2015 54
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2015 - October 2015 57
5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, October 2015 58
5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, October 2015 59
5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, October 2015 59
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 60
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, October 2015 60
6.1.1 Oncology - Deals of the Month 61
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, October 2015 64
6.2.1 Central Nervous System - Deals of the Month 65
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, October 2015 67
6.3.1 Infectious Diseases - Deals of the Month 68
6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, October 2015 70
6.4.1 Cardiovascular - Deals of the Month 72
6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, October 2015 73
6.5.1 Immunology - Deals of the Month 74
6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, October 2015 76
6.6.1 Gastrointestinal - Deals of the Month 77
6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, October 2015 79
6.7.1 Metabolic Disorders - Deal of the Month 80
7 Deal Summary by Geography 83
7.1 Pharmaceuticals & Healthcare, North America Deals, October 2015 83
7.1.1 North America - Deals of the Month 84
7.2 Pharmaceuticals & Healthcare, Europe, Deals, October 2015 86
7.2.1 Europe - Deals of the Month 87
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, October 2015 89
7.3.1 Asia-Pacific - Deals of the Month 90
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, October 2015 92
7.4.1 Rest of the World - Deals of the Month 93
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 94
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, May 2015 - October 2015 94
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, May 2015 - October 2015 96
9 Further Information 97
9.1 Methodology 97
9.2 About GlobalData 98
9.3 Disclosure information 99
9.4 Disclaimer 99

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, October 2015 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), October 2015 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2015 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2015 - October 2015 23
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 25
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, October 2015 25
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 26
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 28
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, October 2015 28
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, May 2015 - October 2015 30
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), October 2015 31
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 32
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2015 - October 2015 33
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 35
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 36
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2015 - October 2015 37
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), October 2015 38
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2015 - October 2015 40
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2015 - October 2015 43
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), May 2015 - October 2015 45
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 47
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2015 - October 2015 49
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 51
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), October 2015 53
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2015 - October 2015 56
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2015 58
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, October 2015 58
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, October 2015 59
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, October 2015 59
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 61
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 65
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 68
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 71
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 74
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 77
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 80
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 84
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 87
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 90
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 93
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 95
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 96

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), October 2015 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), October 2015 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 20
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2015 - October 2015 22
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 24
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 26
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 27
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2015 - October 2015 29
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), October 2015 30
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), October 2015 31
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 32
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 34
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 36
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2015 - October 2015 37
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2015 - October 2015 39
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2015 - October 2015 41
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2015 - October 2015 42
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2015 - October 2015 44
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 46
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2015 - October 2015 48
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 50
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2015 - October 2015 52
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, May 2015 - October 2015 54
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), May 2015 - October 2015 55
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), October 2015 57
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 60
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 64
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 67
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 70
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 73
Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 76
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 79
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 83
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 86
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 89
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 92
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 94
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2015 - October 2015 96

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".